New York, NY -- (SBWIRE) -- 04/23/2013 -- Keryx Biopharmaceuticals (NASDAQ:KERX) traded at $ 8.32 in the last session, which is +0.29 (3.61%). The stock has a Range of 8.06 - 8.64. The stock has a 52 week low and high of 1.34 - 9.98 respectively. The stock has a Market Cap of 679.58M. The stock traded a volume of 6.27M. The stock has a 30 day average volume of 2.70M.
Keryx Biopharmaceuticals, Inc. (Keryx) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. The Company is developing KRX-0401, an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, and also affects a number of other key signal transduction pathways, including the Jun N-terminal kinases pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and survival.
Find out where KERX could be headed here:
Nuance Communications, Inc. (NASDAQ: NUAN) announced that its intuitive voice capabilities power the HTC Car application on the new HTC One smartphone. Now, people can take command of their HTC One while minimizing distraction behind the wheel in more than 20 languages.
HTC Car integrates Nuance’s powerful voice recognition capabilities to give people quick and direct access to people, local business information, navigation, music on the device, streaming content from TuneIn, and more. Further, hands-free command and control is available, including hands-free text messaging that lets people hear incoming text messages read aloud, and respond without having to manually or visually engage the device – keeping people connected behind the wheel in a safer, smarter way.
Nuance Communications, Inc. (NUAN) is a leading provider of voice and language solutions for businesses and consumers around the world.
Find out more on NUAN here:
MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.MonsterTradingAlerts.com
Disclosure: MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/
Alexander K. Neumann
Monster Trading Alerts
For more information on this press release visit: http://www.sbwire.com/press-releases/keryx-biopharmaceuticals-and-nuance-communications-analysis-nasdaq-kerx-nasdaq-nuan-241256.htm